Loading...
Market
How many patients will be using Wegovy in China by end of 2024?
3
Resolution / Starting Odds
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
Reports from Novo Nordisk or independent health market researchers
Story
Novo Nordisk's Wegovy Weight-Loss Drug Approved in China, Shares Rise 1.8% Pre-Market
Jun 25, 2024, 10:35 AM
Novo Nordisk's weight-loss drug Wegovy has been approved for long-term weight management in China. The approval by China's National Medical Products Administration, announced on Tuesday via the company's official WeChat account, will allow Novo Nordisk to market Wegovy in the world's second-largest economy, which has the highest number of overweight or obese people. Wegovy, also known as semaglutide, claims to help reduce body weight by 17%, or an average of 16.8 kg. Initially, the company will focus on patients paying out-of-pocket for the weekly injectable drug. This approval is significant as Novo Nordisk faces a tight timeline with its semaglutide patent set to expire soon. Novo Nordisk has also promised to prioritize existing patients amid shortages. The company's shares rose by 1.8% pre-market following the announcement.
View original story
Similar markets
Price competitiveness • 25%
Efficacy and safety profile • 25%
Marketing and distribution • 25%
Regulatory support • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
Above 150,000 • 25%
Shanghai • 25%
Beijing • 25%
Guangzhou • 25%
Other • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
Weight Loss • 25%
Reduced Heart Attack Risk • 25%
Improved Overall Health • 25%
Other • 25%
Above 50% • 25%
30%-50% • 25%
10%-30% • 25%
Below 10% • 25%
Below $1 billion • 25%
$1 billion to $1.5 billion • 25%
$1.5 billion to $2 billion • 25%
Above $2 billion • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%